On Invalid Date, Castle Biosciences (NASDAQ: CSTL) reported Q2 2024 earnings per share (EPS) of $0.32, up 145.71% year over year. Total Castle Biosciences earnings for the quarter were $8.92 million. In the same quarter last year, Castle Biosciences's earnings per share (EPS) was -$0.70.
As of Q3 2024, Castle Biosciences's earnings has grown year over year. Castle Biosciences's earnings in the past year totalled -$3.10 million.
What is CSTL's earnings date?
Castle Biosciences's earnings date is Invalid Date. Add CSTL to your watchlist to be reminded of CSTL's next earnings announcement.
What was CSTL's revenue last quarter?
On Invalid Date, Castle Biosciences (NASDAQ: CSTL) reported Q2 2024 revenue of $87.00 million up 73.53% year over year. In the same quarter last year, Castle Biosciences's revenue was $50.14 million.
What was CSTL's revenue growth in the past year?
As of Q3 2024, Castle Biosciences's revenue has grown 71.67% year over year. This is 72.06 percentage points higher than the US Diagnostics & Research industry revenue growth rate of -0.39%. Castle Biosciences's revenue in the past year totalled $287.59 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.